network member

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

About Network Member

The mission of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is to go beyond the cutting edge in science and medicine to perform the most advanced research and translate the discoveries into the very best cancer therapies. The Kimmel Cancer Center, which opened in 1973, has active programs in clinical research, laboratory research, education, community outreach, and prevention and control. The strength of its research and treatment programs was recognized early on by the National Cancer Institute (NCI). The center became one of the first to earn Comprehensive Cancer Center status and recognition as a “Center of Excellence,” and is one of only 41 cancer centers in the country designated as such. It is the only Comprehensive Cancer Center in the state of Maryland. Website: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Currently Enrolling

HCRN-GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243
Columbia University Irving Medical Center
Fox Chase Cancer Center
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
University of Iowa Holden Comprehensive Cancer Center
Currently Enrolling

HCRN-GU20-436

NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations
Cancer areas:Prostate
Columbia University Irving Medical Center
Memorial Sloan Kettering Cancer Center
Moores Cancer Center at UC San Diego Health
Penn Medicine Abramson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Currently Enrolling

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Cancer areas:Breast
Dana-Farber Cancer Institute
Duke Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The University of Chicago Medicine Comprehensive Cancer Center
UC San Francisco
University of Alabama at Birmingham Comprehensive Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Enrollment Closed

HCRN-GU16-287

Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer
Huntsman Cancer Institute at the University of Utah
Icahn School of Medicine at Mount Sinai
Rutgers Cancer Institute of New Jersey
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Vanderbilt-Ingram Cancer Center